Create an Account

Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Meeting report with presentation slides, videos and online CME of a PACE-CME symposium held during ESC 2021, The Digital Experience.

Episodes 1-3 of 3

  • Integrating EPAbased therapy in the management of residual CV riskIntegrating EPAbased therapy in the management of residual CV risk
    Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides
    Integrating EPA-based therapy in the management of residual CV risk
    • Prof. Ph. Gabriel Steg, MD
      Prof. Ph. Gabriel Steg, MD

      Prof. Ph. Gabriel Steg, MD

  • What is the evidence of EPAbased therapy for CV prevention What is the evidence of EPAbased therapy for CV prevention
    Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides
    What is the evidence of EPA-based therapy for CV prevention?
    • Prof. Lale Tokgözoğlu, MD
      Prof. Lale Tokgözoğlu, MD

      Prof. Lale Tokgözoğlu, MD

  • Unravelling the triglyceride story Unravelling the triglyceride story
    Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides
    Unravelling the triglyceride story
    • prof. Paul Ridker, MD
      prof. Paul Ridker, MD

      prof. Paul Ridker, MD

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Register

    We’re glad to see you’re enjoying PACE-CME…
    but how about a more personalized experience?

    Register for free
    You are now leaving PACE-CME and going to a site run by another organization.

    Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.